The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Issue 16 (15th April 2015)

• Record Type: Journal Article
• Authors: Norton, Elizabeth B.; Bauer, David L.; Weldon, William C.; Oberste, M. Steven; Lawson, Louise B.; Clements, John D.
• Is Part Of: Vaccine. Volume 33:Issue 16(2015)
• Page Start: 1909
• Page End: 1915
• Publication Date: 2015-04-15
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.02.069
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">We evaluated the adjuvant dmLT admixed with inactivated poliovirus vaccine (IPV).</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Fractional IPV doses were delivered intramuscularly or intradermally in mice.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">dmLT adjuvant enables dose-sparing of IPV, particularly for serotype-1.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">dmLT enhances mucosal immunity and longevity of serum anti-PV neutralizing titers.</p> </list-item> </list> </p> </sec> </abstract>